Addition of the immunotherapy drug pembrolizumab to standard of care for patients with ... The trial was funded by by a SU2C ...

Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...

NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based ...

PITTSBURGH — Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue ...

Citius Pharmaceuticals (CTXR) and Citius Oncology (CTOR) announced “promising” preliminary results from an ongoing ...

For those receiving pembrolizumab, the therapy was initiated at 2-6 weeks ... The study was funded by the Merck Investigator ...

Rahway: Merck, known as MSD outside of the United States and Canada, and Moderna, Inc., announced the initiation of INTerpath ...

Pembrolizumab plus chemotherapy improves disease-free survival (DFS) in patients with high-risk endometrial cancer after surgery with curative intent, according to a study published online Oct. 16 in ...

The clinical trials are sponsored by IO Biotech and conducted in collaboration with Merck, which is supplying pembrolizumab. IO Biotech maintains global commercial rights to IO102-IO103. KEYTRUDA® is ...

First-line pembrolizumab “has consistent antitumor activity and safety” in patients with advanced urothelial carcinoma who are potentially ineligible for platinum‐based chemotherapy, researchers found ...

Merck Research Laboratories. "These approvals underscore the continued expansion of the use of KEYTRUDA in diverse patient populations and treatment settings with utility of KEYTRUDA ranging from ...